Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
Go back to Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 0.67 +0.02 (3.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $0.03 | |||
| Open | $0.66 | 52 Week Low | $0.01 | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.65 | EPS | $0.00 | |||
| Volume | 6,395,728 | |||||
